Trial watch: Chemotherapy with immunogenic cell death inducers.
作者： Erika Vacchelli , Fernando Aranda , Alexander Eggermont , Jérôme Galon , Catherine Sautès-Fridman
关键词:
摘要: … constitute the gold standard approach to characterize immunogenic instances of cell death. In this setting, immunocompetent mice are vaccinated with syngeneic cancer cells that are …
sci-hub.se 参考文章(249)
Yan Song, Ai-Ping Zhou, Qiong Qin, Lin Yang, Jin-Wan Wang, Yihebali Chi, Jing Huang, A phase II trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer. Chinese Medical Journal. ,vol. 126, pp. 3470- 3474 ,(2013)
Lorenzo Galluzzi, Tom Vanden Berghe, Nele Vanlangenakker, Sabrina Buettner, Tobias Eisenberg, Peter Vandenabeele, Frank Madeo, Guido Kroemer, Programmed necrosis from molecules to health and disease. International Review of Cell and Molecular Biology. ,vol. 289, pp. 1- 35 ,(2011) , 10.1016/B978-0-12-386039-2.00001-8
Edward J. Kim, Edgar Ben-Josef, Joseph M. Herman, Tanios Bekaii-Saab, Laura A. Dawson, Kent A. Griffith, Isaac R. Francis, Joel K. Greenson, Diane M. Simeone, Theodore S. Lawrence, Daniel Laheru, Christopher L. Wolfgang, Terence Williams, Mark Bloomston, Malcolm J. Moore, Alice Wei, Mark M. Zalupski, A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer Cancer. ,vol. 119, pp. 2692- 2700 ,(2013) , 10.1002/CNCR.28117
Myron Karon, Stuart E. Siegel, Felicidad Avila, Richard L. Momparler, Effect of Adriamycin on DNA, RNA, and Protein Synthesis in Cell-free Systems and Intact Cells Cancer Research. ,vol. 36, pp. 2891- 2895 ,(1976)
Abhishek D. Garg, Aleksandra M. Dudek, Patrizia Agostinis, Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors. ,vol. 39, pp. 355- 367 ,(2013) , 10.1002/BIOF.1125
Bruce A. Chabner, Thomas G. Roberts, Chemotherapy and the war on cancer Nature Reviews Cancer. ,vol. 5, pp. 65- 72 ,(2005) , 10.1038/NRC1529
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381
Raymonde Busch, Natali Pflug, Nicole Weit, Anne Westermann, Anna-Maria Fink, Paula Cramer, Nina Reinart, Dirk Winkler, Günter Fingerle-Rowson, Stephan Stilgenbauer, Hartmut Döhner, Gabriele Kandler, Barbara Eichhorst, Michael Hallek, Marco Herling, Georg Hopfinger, Sequential Chemoimmunotherapy of Fludarabine, Mitoxantrone, and Cyclophosphamide Induction Followed by Alemtuzumab Consolidation Is Effective in T-cell Prolymphocytic Leukemia Cancer. ,vol. 119, pp. 2258- 2267 ,(2013) , 10.1002/CNCR.27972
Amal Halim, Niveen Abotouk, Methotrexate‐paclitaxel‐epirubicin‐carboplatin as second‐line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin‐gemcitabine: A phase II study Asia-pacific Journal of Clinical Oncology. ,vol. 9, pp. 60- 65 ,(2013) , 10.1111/J.1743-7563.2012.01554.X
Raymond B. Weiss, The anthracyclines: will we ever find a better doxorubicin? Seminars in Oncology. ,vol. 19, pp. 670- 686 ,(1992) , 10.5555/URI:PII:009377549290036Z